Using engineered natural killer cells to treat bone cancer
Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma
This study is testing a new treatment for bone cancer called osteosarcoma by using specially modified immune cells that can better find and kill cancer cells, aiming to offer a safer and more effective option for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10887434 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy using genetically modified natural killer (NK) cells to target and kill osteosarcoma cells, a type of bone cancer. The approach involves engineering NK cells to enhance their ability to recognize and destroy cancer cells, potentially overcoming some limitations of traditional CAR-T cell therapies. By utilizing NK cells, which can attack tumors without the complications associated with T cells, this research aims to provide a safer and more effective treatment option for patients. The study will explore how these engineered NK cells can be used in a clinical setting to improve outcomes for patients with osteosarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with osteosarcoma who have not responded to standard treatments.
Not a fit: Patients with other types of cancer or those who are not diagnosed with osteosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel and effective treatment for patients with osteosarcoma, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results using engineered NK cells in cancer therapies, indicating potential for success in this novel application.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Robbins, Gabrielle Matilde — University of Minnesota
- Study coordinator: Robbins, Gabrielle Matilde
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.